Pacira BioSciences, Inc. (NASDAQ:PCRX) — Market Cap & Net Worth
Market Cap & Net Worth: Pacira BioSciences, Inc. (PCRX)
Pacira BioSciences, Inc. (NASDAQ:PCRX) has a market capitalization of $989.57 Million ($989.57 Million) as of May 2, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #9165 globally and #2437 in its home market, demonstrating a -3.63% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Pacira BioSciences, Inc.'s stock price $24.44 by its total outstanding shares 40489894 (40.49 Million). Analyse Pacira BioSciences, Inc. cash conversion from operations to see how efficiently the company converts income to cash.
Pacira BioSciences, Inc. Market Cap History: 2015 to 2026
Pacira BioSciences, Inc.'s market capitalization history from 2015 to 2026. Data shows change from $3.11 Billion to $989.57 Million (-4.82% CAGR).
Index Memberships
Pacira BioSciences, Inc. is a constituent of 4 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.41 Trillion | 0.04% | #251 of 976 |
|
NASDAQ Composite
IXIC
|
$38.77 Trillion | 0.00% | #939 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.67 Trillion | 0.06% | #150 of 263 |
|
S&P Small-Cap 600 Index
SML
|
$1.54 Trillion | 0.10% | #469 of 602 |
Weight: Pacira BioSciences, Inc.'s market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Pacira BioSciences, Inc. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Pacira BioSciences, Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
1.44x
Pacira BioSciences, Inc.'s market cap is 1.44 times its annual revenue
Latest Price to Earnings (P/E) Ratio
148.97x
Pacira BioSciences, Inc.'s market cap is 148.97 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $1.31 Billion | $276.37 Million | -$37.95 Million | 4.73x | N/A |
| 2017 | $1.85 Billion | $286.63 Million | -$42.61 Million | 6.45x | N/A |
| 2018 | $1.74 Billion | $337.28 Million | -$471.00K | 5.16x | N/A |
| 2019 | $1.83 Billion | $421.03 Million | -$11.02 Million | 4.36x | N/A |
| 2020 | $2.42 Billion | $429.65 Million | $145.52 Million | 5.64x | 16.65x |
| 2021 | $2.44 Billion | $541.53 Million | $41.98 Million | 4.50x | 58.03x |
| 2022 | $1.56 Billion | $666.82 Million | $15.91 Million | 2.34x | 98.27x |
| 2023 | $1.37 Billion | $674.98 Million | $41.95 Million | 2.02x | 32.56x |
| 2024 | $762.83 Million | $700.97 Million | -$99.56 Million | 1.09x | N/A |
| 2025 | $1.05 Billion | $726.41 Million | $7.03 Million | 1.44x | 148.97x |
Competitor Companies of PCRX by Market Capitalization
Companies near Pacira BioSciences, Inc. in the global market cap rankings as of May 2, 2026.
Key companies related to Pacira BioSciences, Inc. by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #499 globally with a market cap of $52.60 Billion USD.
- Zoetis Inc (NYSE:ZTS): Ranked #525 globally with a market cap of $50.31 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #526 globally with a market cap of $50.29 Billion USD ( CN¥343.70 Billion CNY).
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #572 globally with a market cap of $45.88 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #499 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #525 | Zoetis Inc | NYSE:ZTS | $50.31 Billion | $114.16 |
| #526 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $50.29 Billion | CN¥53.88 |
| #572 | GALDERMA GROUP AG | NYSE:GALDY | $45.88 Billion | $42.09 |
Pacira BioSciences, Inc. Historical Marketcap From 2015 to 2026
Between 2015 and today, Pacira BioSciences, Inc.'s market cap moved from $3.11 Billion to $ 989.57 Million, with a yearly change of -4.82%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $989.57 Million | -5.56% |
| 2025 | $1.05 Billion | +37.37% |
| 2024 | $762.83 Million | -44.16% |
| 2023 | $1.37 Billion | -12.61% |
| 2022 | $1.56 Billion | -35.83% |
| 2021 | $2.44 Billion | +0.55% |
| 2020 | $2.42 Billion | +32.10% |
| 2019 | $1.83 Billion | +5.30% |
| 2018 | $1.74 Billion | -5.76% |
| 2017 | $1.85 Billion | +41.33% |
| 2016 | $1.31 Billion | -57.94% |
| 2015 | $3.11 Billion | -- |
End of Day Market Cap According to Different Sources
On May 2nd, 2026 the market cap of Pacira BioSciences, Inc. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $989.57 Million USD |
| MoneyControl | $989.57 Million USD |
| MarketWatch | $989.57 Million USD |
| marketcap.company | $989.57 Million USD |
| Reuters | $989.57 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Pacira BioSciences, Inc.
Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension for postsurgical pain management; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension ind… Read more